On November 24, a license contract has been signed by Algiax Pharmaceuticals GmbH and CureDiab Metabolic Research GmbH. Under this contract, CureDiab now has the exclusive, global rights to develop and commercialise the thioacrylamide-derivatives HK1 and HK3 for treatment of NAFLD/NASH. We are very happy about this agreement and look forward to a fruitful collaboration with Algiax Pharmaceuticals.